No Data
No Data
Affected by the centralized procurement, yabao pharmaceutical group: the cancellation of product network qualification by hebei has a relatively small impact on profits. | Live coverage of the earnings conference
①The chairman of Yabao Pharmaceutical Group stated that the cancellation of the qualification for several products by Hebei only had a small impact on the profits. ②The sales of H1 Betacismol Hydrochloride Injection decreased under the influence of centralized procurement, leading to a slight decrease in the company's sales revenue. ③Sales of Dinggui Erqin Patch are seasonal, with a slight decrease in revenue in the second quarter.
Yabao Pharmaceutical Group Co., Ltd. 2024 Semi-annual Report
Summary of the 2024 interim report of Yabao Pharmaceutical Group Co., Ltd.
Yabao Pharmaceutical Group (600351.SH) plans to spend between 0.1 billion yuan and 0.15 billion yuan to buy back shares.
Yabao Pharmaceutical Group (600351.SH) announced on August 14 that the repurchased shares will be cancelled in accordance with the law and the registered capital of the company will be reduced. The total amount of funds to be repurchased is not less than RMB 0.1 billion (inclusive) and not more than RMB 0.15 billion (inclusive), and the repurchase price does not exceed RMB 6.95 per share (inclusive).
Yabao Pharmaceutical Group (600351.SH): net income of 0.18 billion yuan in the first half of the year, a year-on-year increase of 6.99%.
Yabao Pharmaceutical Group (600351.SH) released its semi-annual report on August 14th. During the reporting period, the company achieved revenues of 1.444 billion yuan, a decrease of 5.82% year-on-year, and net income attributable to shareholders of the listed company of 0.18 billion yuan, an increase of 6.99% year-on-year. The company focuses on its advantages and resources to build a platform for the R&D of generic drugs, and focuses on the R&D of high-end generic drug products with high technological barriers and cost advantages. Currently, the company has established high-difficulty preparation technology platforms such as transdermal patches, complex injections, topical ointments, and sustained-release formulations, and has successfully promoted the R&D of pipeline products during the reporting period.
Yabao Pharmaceutical Group Gets Supplementary Drug Approval for High-Blood Pressure Tablets
No Data
No Data